Search Within

Heiko Schoder

  1. "GSK Faculty"
Formats
  1. Journal Article (94)
  2. Meeting Abstract (56)
  3. Book Section (4)
  4. Review (3)
  5. Editorial (2)
  6. Research Letter (2)
Groups
  1. GSK Faculty (161)
  2. Molecular Imaging and Therapy Service (161)
  3. Radiology, Department of (161)
  4. Molecular Pharmacology and Chemistry Program Faculty (117)
  5. Sloan Kettering Institute Faculty (117)
  6. Department of Medicine (90)

More Groups

People
  1. Steven Larson (93)
  2. John Humm (41)
  3. Mithat Gonen (28)
  4. Howard Scher (23)
  5. Henry Yeung (22)
  6. Josef Fox (22)

More People

Years
  1. 2025 (5)
  2. 2024 (13)
  3. 2023 (15)
  4. 2022 (3)
  5. 2021 (10)
  6. 2020 (9)

More Years

Publications
  1. Journal of Nuclear Medicine (40)
  2. Journal of Clinical Oncology (23)
  3. Blood (12)
  4. European Journal of Nuclear Medicine and Molecular Imaging (12)
  5. International Journal of Radiation Oncology, Biology, Physics (9)
  6. Medical Physics (5)

More Publications

Publishers
  1. Society of Nuclear Medicine (40)
  2. American Society of Clinical Oncology (23)
  3. Springer (21)
  4. Elsevier Inc. (16)
  5. American Society of Hematology (13)
  6. Lippincott Williams & Wilkins (8)

More Publishers

Results (161)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • [(18)F]-fluorocholine uptake correlates with pathologic evidence of recurrent tumor after SRS for brain metastases
    Meeting Abstract

    Kohutek, Z. A.; Blasberg, R. G.; Humm, J.; Blumberg, L. E.; Brennan, C. W.; Tabar, V.; Gutin, P. H.; Beattie, B.; Rosenblum, M.; Huse, J. T.; more...
    International Journal of Radiation Oncology, Biology, Physics (2016)

    Fulltext@MSK | Save
  • A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma
    Journal Article

    Shoushtari, A. N.; Ong, L. T.; Schoder, H.; Singh-Kandah, S.; Abbate, K. T.; Postow, M. A.; Callahan, M. K.; Wolchok, J.; Chapman, P. B.; Panageas, K. S.; more...
    Melanoma Research (2016)

    Fulltext@MSK | Save
  • Prospective study of 3′-deoxy-3′-(18)F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma
    Journal Article

    Schoder, H.; Zelenetz, A. D.; Hamlin, P.; Gavane, S.; Horwitz, S.; Matasar, M.; Moskowitz, A.; Noy, A.; Palomba, L.; Portlock, C.; more...
    Journal of Nuclear Medicine (2016)

    Fulltext@MSK | Save
  • Rest and stress Rb-82 PET myocardial perfusion imaging as a predictor of perioperative cardiac events in cancer patients
    Meeting Abstract

    Fox, J.; Gupta, D.; Yu, A.; Gandikota, N.; Larson, S.; Schoder, H.; Strauss, H. W.
    Journal of Nuclear Medicine (2015)

    Fulltext@MSK | Save
  • Pathologic correlation of 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) and FDG PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Feldman, J. L.; Fox, J. J.; Martinez, D. F.; Autio, K. A.; Durack, J. C.; Humm, J.; Schoder, H.; Gavane, S. C.; Curtis, K. R.; Balakirsky, S. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
    Journal Article

    Phillips, E.; Penate-Medina, O.; Zanzonico, P. B.; Carvajal, R. D.; Mohan, P.; Ye, Y.; Humm, J.; Gonen, M.; Kalaigian, H.; Schöder, H.; more...
    Science Translational Medicine (2014)

    Fulltext@MSK | Save
  • Evaluating 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA)
    Meeting Abstract

    Feldman, J. L.; Fox, J. J.; Autio, K. A.; Gavane, S. C.; Heller, G.; Schoder, H.; Humm, J.; Martinez, D. F.; Slovin, S. F.; Scher, H. I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Sadelain, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Riviere, I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib
    Meeting Abstract

    Fox, J. J.; Haupt, E. C.; Humm, J.; Autio, K. A.; Rathkopf, D. E.; Vargas, H. A.; Schöder, H.; Hricak, H.; Larson, S. M.; Scher, H. I.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save